SLC5A2 and cardiovascular disorder: As we have shown previously, SGLT2 inhibitors are prescribed to a different population in UK primary care compared to patients enrolled in recent major outcome trials (Table S13).23 Participants in our study were younger, with better renal function, and included a lower proportion of people with cardiovascular disease, heart failure and retinopathy.